Establishment Labs Holdings Inc. $ESTA Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC decreased its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 6.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 668,313 shares of the company’s stock after selling 45,738 shares during the quarter. William Blair Investment Management LLC owned about 2.24% of Establishment Labs worth $42,886,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. KBC Group NV purchased a new stake in shares of Establishment Labs in the first quarter worth $28,000. Integrated Wealth Concepts LLC bought a new position in shares of Establishment Labs during the second quarter valued at $32,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Establishment Labs in the 2nd quarter worth about $43,000. Sterling Capital Management LLC raised its position in shares of Establishment Labs by 849.5% in the 3rd quarter. Sterling Capital Management LLC now owns 902 shares of the company’s stock worth $58,000 after purchasing an additional 807 shares during the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in shares of Establishment Labs in the 3rd quarter worth about $80,000. 72.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ESTA. Needham & Company LLC upped their price target on shares of Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Stifel Nicolaus began coverage on shares of Establishment Labs in a research note on Wednesday, October 14th. They set a “buy” rating and a $85.00 price objective for the company. Citigroup raised shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 target price for the company in a report on Thursday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, September 21st. Finally, BTIG Research dropped their target price on shares of Establishment Labs from $103.00 to $93.00 and set a “buy” rating on the stock in a research note on Thursday, October 29th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.00.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA traded up $2.13 during trading on Friday, hitting $70.75. The company had a trading volume of 367,353 shares, compared to its average volume of 513,910. The stock has a 50 day simple moving average of $66.04 and a 200 day simple moving average of $72.37. The company has a debt-to-equity ratio of 17.17, a quick ratio of 2.52 and a current ratio of 3.57. Establishment Labs Holdings Inc. has a 12 month low of $53.16 and a 12 month high of $97.59. The firm has a market capitalization of $2.11 billion, a P/E ratio of -55.27 and a beta of 1.03.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Friday, October 30th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.09). Establishment Labs had a negative return on equity of 196.38% and a negative net margin of 14.56%. The firm had revenue of $71.99 million during the quarter, compared to the consensus estimate of $66.81 million. During the same period in the prior year, the company posted ($0.38) EPS. The company’s quarterly revenue was up 33.8% on a year-over-year basis. As a group, analysts anticipate that Establishment Labs Holdings Inc. will post -1.18 earnings per share for the current year.

About Establishment Labs

Establishment Labs Holdings Inc. is a medical technology company focused on breast health and aesthetics. Founded in 2004 by Juan José Chacón-Quirós, the Costa Rica-based company develops and manufactures products for breast augmentation and reconstruction. Its product portfolio includes Motiva breast implants, offered in different shapes and designs, as well as related technologies and products for plastic and reconstructive surgery. The company also develops solutions intended to support surgical procedures and patient care.